The EGM resolved to approve the Board of Directors’ previous resolution on September 22, 2022 on a directed share issue of 2,601,732 shares, whereby the share capital increases by SEK 650,433.
The minutes from the EGM (in Swedish) will be available on Lipum’s website, www.lipum.se/bolagsstyrning/.
For further information please contact:
Einar Pontén, CEO
Mobile phone: +46 70 578 34 95
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The Company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The Company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.